



PC8626CJTJ

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 23rd day of September 2003.

By

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

William J. Curatolo, et al.

APPLICATION NO.: 09/803,628

FILING DATE: March 9, 2001

TITLE: Controlled-Release Dosage Forms of Azithromycin

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: SEPTEMBER 23, 2003

James T. Jones  
James T. Jones  
Attorney for Applicant(s)  
Reg. No. 30,561


Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4903

4/97, M2, (1/1)

RECEIVED

TECH CENTER 1600/2980

10/01/2003 ZJUHR1 00000051 161445 09803628  
01 FC:1806 180.00 DA



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Page 1 of 1

ATTY. DOCKET NO. PC8626CJTJ

SERIAL NO. 09/803,628

**APPLICANT** William J. Curatolo, et al.

FILING DATE March 9, 2001

GROUP 1616

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

			Fiese, et al., Jml of Antimicrobial Chemotherapy, 1990, 25, suppl. A, pgs 39-47
			Anie, et al., Intrnl Jml of Pharmaceutics, 76, 1991, pgs 183-185
			Khosla, et al., Intrnl Jml of Pharmaceutics, 62, 1990, pgs R9-R11
			Knutson, et al., The Am Jml of Gastroenterology, 1989, vol. 84, no. 10, pgs 1278-1284
			Jobin, et al., Br. J. Clin. Pharmac, 1985, 19, pgs 97S-105S
			Blankenhorn, Socl. Exp. Boil. Med, 1955, 88, pgs 356-362
			Graffner, et al., Pharm Research, vol. 7, no. 1, 1990, pgs 54-58
			Fischer, et al., Pharm Research, vol. 4, no. 6, 1987, pgs 480-485
			Welling, P., 1986, ACS Monograph 185, American Chemical Society, pp. 173-178
			Langenbucher, et al., Br. J. Clin. Pharmac, 1985, 19, pgs 151S-162S

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

## INFORMATION DISCLOSUR

4/97, !disclos, 1/1

284  
RECEIVED  
OCT 02 2003  
TECH CENTER 1600/2900